Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.
Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.
Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.
Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.
Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.
Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the role of TKIs in the treatment of HER2-positive breast cancer.
Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.
Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with pancreatic cancer.
Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses the rationale for the CORRELATE trial in metastatic colorectal cancer.
Pamela N. Munster, MD, professor, department of medicine (hematology/oncology), University of California, San Francisco (UCSF), director, early phase clinical trials unit, co-leader, Center for BRCA Research, leader, Experimental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the developmental process for biosimilars in oncology.
Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).
Stephan Grupp, MD, PhD, director, Cancer Immunotherapy Program, director, Translational Research for the Center for Childhood Cancer Research, medical director, Stem Cell Laboratory, Children’s Hospital of Philadelphia, discusses the placement of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with acute lymphoblastic leukemia (ALL).
Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.
Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the importance of biosimilars in HER2-positive breast cancer.
Corinne Summers, MD, pediatric oncologist, Seattle Children's Hospital, assistant member, Clinical Research Division, University of Washington Fred Hutchinson Cancer Research Center, discusses the role of CAR T cells in pediatric cancer.
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.
Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses a trial attempting to match pediatric patients with more precise therapy for acute leukemia.
Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.
Ryan B. Corcoran, MD, PhD, clinical researcher, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the future role of liquid biopsies in gastrointestinal cancers.
Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.
Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of pertuzumab in HER2-positive breast cancer.
John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses applications for liquid biopsies in gastrointestinal cancer.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.
Stephanie K. Dougan, PhD, assistant professor, Microbiology and Immunobiology, Division of Immunology, Harvard Medical School, researcher, Dana-Farber Cancer Institute, discusses ways of augmenting T-cell immunity in pancreatic cancer.
Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses an emerging combination in the treatment of patients with mantle cell lymphoma.
Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses next steps with immunotherapy in the treatment of patients with metastatic colorectal cancer.
Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the potential for immunotherapy in metastatic colorectal cancer.
Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.
Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses ways of reducing the cost of chimeric antigen receptor (CAR) T-cell therapy.
